drugset
drugset / Trial / NCT01655407

Safety and Efficacy Study of Autologous Engineered Skin Substitute to Treat Partial- and Full-Thickness Burn Wounds

NCT01655407 ↗

Phase 2 Unknown 10 enrolled Amarantus BioScience Holdings, Inc. Amarex Clinical Research · collab
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this research study is to test how well the investigational treatment, Engineered Skin Substitutes (ESS-W), works for covering and treating burn wounds. The areas of the body that are treated with ESS-W will be compared to similar areas treated with the patient's own skin (split-thickness skin autograft (AG)). A skin autograft (AG) will be performed by taking healthy skin from one area of the body and placing it on the burned area.

Timeline

Start
2016-09
Primary completion
2019-12
Completion
2020-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Autologous Engineered Skin Substitute Unknown — —

Indications

No indication recorded.